| Cosmeceuticals for the skin: An Overview M Singhal, S Khanna, N Atul Asian Journal of Pharmaceutical and Clinical Research 4 (2), 1-6, 2011 | 92 | 2011 |
| The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes C McAdam-Marx, A Dahal, B Jennings, M Singhal, K Gunning Journal of managed care & specialty pharmacy 21 (6), 452-468, 2015 | 59 | 2015 |
| Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer DD Stenehjem, M Yoo, SK Unni, M Singhal, H Bauer, K Saverno, C Quah, ... Breast Cancer: Targets and Therapy, 169-177, 2014 | 28 | 2014 |
| Real-world evidence in pain research: a review of data sources BK Bellows, KL Kuo, E Biltaji, M Singhal, T Jiao, Y Cheng, ... Journal of Pain & Palliative Care Pharmacotherapy 28 (3), 294-304, 2014 | 24 | 2014 |
| Glycemic control and weight outcomes for exenatide once weekly versus liraglutide in patients with type 2 diabetes: a 1-year retrospective cohort analysis C McAdam-Marx, H Nguyen, MB Schauerhamer, M Singhal, S Unni, X Ye, ... Clinical Therapeutics 38 (12), 2642-2651, 2016 | 23 | 2016 |
| Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and … RA Kloner, E Stanek, CL Crowe, M Singhal, RS Pepe, J Bradsher, ... The journal of sexual medicine 20 (1), 38-48, 2023 | 14 | 2023 |
| Real-world glycemic control from GLP-1RA therapy with and without concurrent insulin in patients with type 2 diabetes M Singhal, S Unni, M Schauerhamer, H Nguyen, J Hurd, C McAdam-Marx Journal of Managed Care & Specialty Pharmacy 23 (3), 267-275, 2017 | 12 | 2017 |
| Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes. N Pemmaraju, J Yu, S Parasuraman, D Paranagama, J Kish, J Visaria, ... Journal of Clinical Oncology 38 (15_suppl), e19535-e19535, 2020 | 6 | 2020 |
| Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA M Singhal, H Tan, CI Coleman, M Han, C Nguyen, M Ingham BMJ Open Diabetes Research and Care 7 (1), e000704, 2019 | 5 | 2019 |
| Association of uncontrolled blood pressure in apparent treatment‐resistant hypertension with increased risk of major adverse cardiovascular events plus G Bakris, C Chen, AK Campbell, V Ashton, L Haskell, M Singhal The Journal of Clinical Hypertension 25 (8), 737-747, 2023 | 3 | 2023 |
| Ruxolitinib re-treatment in patients with myelofibrosis: real-world evidence on patient characteristics and outcomes AT Gerds, J Yu, RM Scherber, D Paranagama, JK Kish, J Visaria, ... Acta haematologica 145 (4), 448-453, 2022 | 3 | 2022 |
| Treatment experiences with CDK4&6 inhibitors among women with metastatic breast cancer: a qualitative study JJ Stephenson, JC Gable, R Zincavage, GL Price, C Churchill, E Zhu, ... Patient preference and adherence, 2417-2429, 2021 | 3 | 2021 |
| Effect of daily or weekly GLP-1 receptor agonists on glycemic control in insulin-naive patients with poorly controlled type 2 diabetes: a real-world study M Singhal, H Nguyen, M Schauerhamer, S Unni, D Cobden, ... Value in Health 18 (3), A54, 2015 | 3 | 2015 |
| Treatment patterns and clinical outcomes among patients with biliary tract cancers in a large commercially insured US population. A Valderrama, M Singhal, L Wang, B Nepal, S Kamble, M Grabner, ... Journal of Clinical Oncology 40 (4_suppl), 398-398, 2022 | 2 | 2022 |
| Health care resource utilization (HCRU) and costs in patients with biliary tract cancer (BTC) treated with systemic therapy in the United States (US). L Wang, M Singhal, M Eluri, A Valderrama, B Nepal, S Kamble, ... Journal of Clinical Oncology 40 (16_suppl), 4090-4090, 2022 | 1 | 2022 |
| PCN221 Treatment Patterns Including Adherence/Persistence with Cyclin-Dependent Kinase 4&6 Inhibitors (CDK4&6I) Among US Commercially Insured Women with Metastatic Breast … M Singhal, B Nepal, MJ Fisch, D Debono, M Grabner, JJ Stephenson, ... Value in Health 23, S462, 2020 | 1 | 2020 |
| Real-world comparative effectiveness, treatment patterns, and costs in type 2 diabetes mellitus (T2DM) patients initiated on canagliflozin 300 mg (CANA) or a glucagon-like … M Singhal, HJ TAN, CI Coleman, WH Herman, J Cai, M Han, M Ingham Diabetes 67 (Supplement_1), 2018 | 1 | 2018 |
| Role Of Glycemic Control In Development Of Atrial Fibrillation In Patients With Type 2 Diabetes Mellitus M Singhal, C McAdam-Marx, J LaFleur, DM Witt, RE Nelson, JE Biskupiak Value in Health 19 (3), A10, 2016 | 1 | 2016 |
| Association of Atrial Fibrosis With Major Adverse Cardiac Events in Patients With Non-valvular Atrial Fibrillation JB King, M Singhal, G Kaur, K Johnson, C Pacchia, J Biskupiak, ... Circulation 132 (suppl_3), A16572-A16572, 2015 | 1 | 2015 |
| Assessment of single-institution HER2 testing patterns, rate of HER2+ disease, and utilization of trastuzumab in early breast cancer. DD Stenehjem, M Yoo, SK Unni, M Singhal, H Bauer, K Saverno, ... Journal of Clinical Oncology 31 (31_suppl), 124-124, 2013 | 1 | 2013 |
Karen GunningUniversity of UtahVerified email at hsc.utah.edu
